Advanced Enzyme Technologies Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Advanced Enzyme Technologies wird ein jährliches Gewinn- und Umsatzwachstum von 10% bzw. 12.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.2% betragen.
Wichtige Informationen
10.0%
Wachstumsrate der Gewinne
10.16%
EPS-Wachstumsrate
| Chemicals Gewinnwachstum | 19.4% |
| Wachstumsrate der Einnahmen | 12.3% |
| Zukünftige Eigenkapitalrendite | 12.20% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 05 Feb 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.Narrativ-Update • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.Narrativ-Update • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.Narrativ-Update • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.Narrativ-Update • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.Narrativ-Update • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrativ-Update • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analyseartikel • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...Neues Narrativ • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.Analyseartikel • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analyseartikel • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Analyseartikel • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Analyseartikel • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...Analyseartikel • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...Analyseartikel • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...Analyseartikel • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analyseartikel • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analyseartikel • Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Analyseartikel • Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analyseartikel • May 13
With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Analyseartikel • Mar 28
Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Analyseartikel • Mar 13
The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a...Analyseartikel • Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
We note that a Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) insider, Madhusudan Soni, recently sold ₹5.7m...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2028 | 9,970 | 2,053 | 733 | 1,678 | 1 |
| 3/31/2027 | 8,535 | 1,729 | 876 | 1,441 | 1 |
| 3/31/2026 | 7,806 | 1,687 | 1,044 | 1,568 | N/A |
| 12/31/2025 | 7,096 | 1,522 | N/A | N/A | N/A |
| 9/30/2025 | 7,067 | 1,474 | 1,323 | 1,643 | N/A |
| 6/30/2025 | 6,683 | 1,369 | N/A | N/A | N/A |
| 3/31/2025 | 6,369 | 1,311 | 1,077 | 1,425 | N/A |
| 12/31/2024 | 6,275 | 1,329 | N/A | N/A | N/A |
| 9/30/2024 | 6,194 | 1,371 | 904 | 1,422 | N/A |
| 6/30/2024 | 6,311 | 1,386 | N/A | N/A | N/A |
| 3/31/2024 | 6,239 | 1,333 | 941 | 1,414 | N/A |
| 12/31/2023 | 6,048 | 1,371 | N/A | N/A | N/A |
| 9/30/2023 | 5,859 | 1,248 | 965 | 1,327 | N/A |
| 6/30/2023 | 5,668 | 1,166 | N/A | N/A | N/A |
| 3/31/2023 | 5,406 | 1,056 | 1,022 | 1,404 | N/A |
| 12/31/2022 | 5,337 | 979 | N/A | N/A | N/A |
| 9/30/2022 | 5,251 | 960 | 806 | 1,164 | N/A |
| 6/30/2022 | 5,135 | 995 | N/A | N/A | N/A |
| 3/31/2022 | 5,294 | 1,196 | 941 | 1,223 | N/A |
| 12/31/2021 | 5,309 | 1,268 | N/A | N/A | N/A |
| 9/30/2021 | 5,350 | 1,424 | 1,127 | 1,374 | N/A |
| 6/30/2021 | 5,325 | 1,500 | N/A | N/A | N/A |
| 3/31/2021 | 5,018 | 1,459 | 1,434 | 1,630 | N/A |
| 12/31/2020 | 4,820 | 1,459 | N/A | N/A | N/A |
| 9/30/2020 | 4,569 | 1,364 | 978 | 1,472 | N/A |
| 6/30/2020 | 4,481 | 1,301 | N/A | N/A | N/A |
| 3/31/2020 | 4,440 | 1,293 | 904 | 1,409 | N/A |
| 12/31/2019 | 4,480 | 1,302 | N/A | N/A | N/A |
| 9/30/2019 | 4,366 | 1,210 | N/A | 1,276 | N/A |
| 6/30/2019 | 4,288 | 1,148 | N/A | N/A | N/A |
| 3/31/2019 | 4,220 | 1,111 | N/A | 1,286 | N/A |
| 12/31/2018 | 4,194 | 1,061 | N/A | N/A | N/A |
| 9/30/2018 | 4,261 | 1,068 | N/A | N/A | N/A |
| 6/30/2018 | 4,199 | 1,039 | N/A | N/A | N/A |
| 3/31/2018 | 3,918 | 901 | N/A | 1,160 | N/A |
| 12/31/2017 | 3,660 | 837 | N/A | N/A | N/A |
| 9/30/2017 | 3,213 | 725 | N/A | N/A | N/A |
| 6/30/2017 | 3,127 | 793 | N/A | N/A | N/A |
| 3/31/2017 | 3,290 | 915 | N/A | 1,074 | N/A |
| 12/31/2016 | 3,260 | 942 | N/A | N/A | N/A |
| 9/30/2016 | 3,404 | 998 | N/A | N/A | N/A |
| 6/30/2016 | 3,184 | 854 | N/A | N/A | N/A |
| 3/31/2016 | 2,938 | 759 | N/A | 934 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ADVENZYMESDas prognostizierte Gewinnwachstum (10% pro Jahr) liegt über der Sparquote (6.9%).
Ertrag vs. Markt: ADVENZYMESDie Erträge des Unternehmens (10% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (16.4% pro Jahr).
Hohe Wachstumserträge: ADVENZYMESDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ADVENZYMESDie Einnahmen des Unternehmens (12.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.8% pro Jahr).
Hohe Wachstumseinnahmen: ADVENZYMESDie Einnahmen des Unternehmens (12.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ADVENZYMESDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.2%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 21:14 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Advanced Enzyme Technologies Limited wird von 4 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |